Tag Archives: sodium-glucose cotransporter-2 inhibitors (SGLT2i)

Introduction Sodium-glucose cotransporter 2 inhibitors Sodium-glucose cotransporter 2 inhibitors (SGLT2i) demonstrate prognostic benefits independent of glycaemic control, most notably in the EMPA-REG OUTCOME trial.1 Subsequent large-scale randomised-controlled trials (RCTs) of SGLT2i consistently demonstrated improved cardiovascular outcomes irrespective of type 2 diabetes (T2D), extending to populations with heart failure (HF) and chronic kidney disease (CKD). This has culminated in the inclusion of SGLT2i in most T2D, HF and CKD guidelines.2 Frailty There is no universally accepted definition of frailty, which may be understood to be an ag

Introduction Sodium-glucose cotransporter-2 inhibitors (SGLT2i) improve symptoms,1 reduce hospitalisations and extend longevity2,3 for patients who have heart failure with reduced ejection fraction (HFrEF). These beneficial effects are observed very early following initiation,4 prompting calls for these agents to be given equal priority to more established therapies,5,6 which has been reflected in recent guidelines.7 Hospitalisation with heart failure (HF) offers the opportunity for optimisation of guideline-directed medical therapy (GDMT) including SGLT2i,8,9 however, the feasibility of doing so has not been reported outside of the artifici